Center for Biologics Evaluation and Research (CBER)
The Center for Biologics Evaluation and Research (CBER) is the FDA division that regulates biological products including vaccines, blood, gene and cell therapies, and related biologics. It oversees their safety, efficacy, and manufacturing quality from development through post-market surveillance.
What is the Center for Biologics Evaluation and Research (CBER)?
The Center for Biologics Evaluation and Research (CBER) is the division of the U.S. Food and Drug Administration responsible for regulating biological products. Its scope includes vaccines, blood and blood components, and advanced therapies such as gene and cell treatments, along with related biologics.
CBER oversees these products throughout their lifecycle, evaluating their safety, effectiveness, and manufacturing quality from development onward. The center applies regulatory standards tailored to biologics, which differ from those for conventional chemical drugs.
Why is CBER important?
Biological products are complex and derived from living sources, which makes their evaluation and manufacturing oversight distinct from that of small-molecule drugs. CBER's role ensures that vaccines, blood products, and cell and gene therapies meet rigorous standards before and after reaching patients.
By overseeing development through post-market surveillance, the center helps maintain the safety and reliability of products that often serve vulnerable populations or address serious conditions. For developers of biologics, CBER review is a defining part of bringing a product to market.
- what is cber
- cber meaning
- center for biologics evaluation and research definition
- what does cber stand for
- fda cber
- cber vs cder